Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing.
Paluch BE, Glenn ST, Conroy JM, Papanicolau-Sengos A, Bshara W, Omilian AR, Brese E, Nesline M, Burgher B, Andreas J, Odunsi K, Eng K, He J, Qin M, Gardner M, Galluzzi L, Morrison CD. Paluch BE, et al. Among authors: nesline m. Oncotarget. 2017 Jan 10;8(2):3197-3205. doi: 10.18632/oncotarget.13691. Oncotarget. 2017. PMID: 27911273 Free PMC article.
Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors.
Conroy JM, Pabla S, Glenn ST, Burgher B, Nesline M, Papanicolau-Sengos A, Andreas J, Giamo V, Lenzo FL, Hyland FCL, Omilian A, Bshara W, Qin M, He J, Puzanov I, Ernstoff MS, Gardner M, Galluzzi L, Morrison C. Conroy JM, et al. Among authors: nesline m. J Mol Diagn. 2018 Jan;20(1):95-109. doi: 10.1016/j.jmoldx.2017.10.001. Epub 2017 Oct 20. J Mol Diagn. 2018. PMID: 29061374 Free article.
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS. Morrison C, et al. Among authors: nesline mk. J Immunother Cancer. 2018 May 9;6(1):32. doi: 10.1186/s40425-018-0344-8. J Immunother Cancer. 2018. PMID: 29743104 Free PMC article.
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab.
George S, Papanicolau-Sengos A, Lenzo FL, Conroy JM, Nesline M, Pabla S, Glenn ST, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Galluzzi L, Morrison C. George S, et al. Among authors: nesline m. Oncoimmunology. 2018 May 29;7(12):e1460298. doi: 10.1080/2162402X.2018.1460298. eCollection 2018. Oncoimmunology. 2018. PMID: 30524881 Free PMC article.
Identification of targets for prostate cancer immunotherapy.
Papanicolau-Sengos A, Yang Y, Pabla S, Lenzo FL, Kato S, Kurzrock R, DePietro P, Nesline M, Conroy J, Glenn S, Chatta G, Morrison C. Papanicolau-Sengos A, et al. Among authors: nesline m. Prostate. 2019 Apr;79(5):498-505. doi: 10.1002/pros.23756. Epub 2019 Jan 6. Prostate. 2019. PMID: 30614027
Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.
Dy GK, Nesline MK, Papanicolau-Sengos A, DePietro P, LeVea CM, Early A, Chen H, Grand'Maison A, Boland P, Ernstoff MS, Edge S, Akers S, Opyrchal M, Chatta G, Odunsi K, Pabla S, Conroy JM, Glenn ST, DeFedericis HT, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Kanehira K, Lenzo FL, Frederick P, Lele S, Galluzzi L, Kuvshinoff B, Morrison C. Dy GK, et al. Among authors: nesline mk. BMC Med Inform Decis Mak. 2019 Jan 18;19(1):14. doi: 10.1186/s12911-019-0743-x. BMC Med Inform Decis Mak. 2019. PMID: 30658646 Free PMC article.
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C. Conroy JM, et al. Among authors: nesline mk. J Immunother Cancer. 2019 Jan 24;7(1):18. doi: 10.1186/s40425-018-0489-5. J Immunother Cancer. 2019. PMID: 30678715 Free PMC article.
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.
Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C. Pabla S, et al. Among authors: nesline mk. J Immunother Cancer. 2019 Feb 1;7(1):27. doi: 10.1186/s40425-019-0506-3. J Immunother Cancer. 2019. PMID: 30709424 Free PMC article.
Oncologist uptake of comprehensive genomic profile guided targeted therapy.
Nesline MK, DePietro P, Dy GK, Early A, Papanicolau-Sengos A, Conroy JM, Lenzo FL, Glenn ST, Chen H, Grand'Maison A, Boland P, Ernstoff MS, Puzanov I, Edge S, Akers S, Opyrchal M, Chatta G, Odunsi K, Frederick P, Lele S, Gardner M, Morrison C. Nesline MK, et al. Oncotarget. 2019 Jul 23;10(45):4616-4629. doi: 10.18632/oncotarget.27047. eCollection 2019 Jul 23. Oncotarget. 2019. PMID: 31384390 Free PMC article.
46 results